Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Alkem Laboratories IPO is a book built issue of Rs 1,349.61 crores.
Alkem Laboratories IPO bidding started from December 8, 2015 and ended on December 10, 2015. The shares got listed on BSE, NSE on December 23, 2015.
Alkem Laboratories IPO price band is set at ₹1020 to ₹1050 per share. The minimum lot size for an application is 14 Shares. The minimum amount of investment required by retail investors is ₹14,700.
Axis Capital Limited, Edelweiss Financial Services Ltd, J.P. Morgan India Private Limited and Nomura Financial Advisory And Securities (India) Pvt Ltd are the book running lead managers of the Alkem Laboratories IPO, while Link Intime India Private Ltd is the registrar for the issue.
Refer to Alkem Laboratories IPO RHP for detailed information.
| IPO Date | December 8, 2015 to December 10, 2015 |
| Listing Date | December 23, 2015 |
| Face Value | ₹2 per share |
| Price Band | ₹1020 to ₹1050 per share |
| Lot Size | 14 Shares |
| Total Issue Size | 12,853,442 shares (aggregating up to ₹1,349.61 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 119,565,000 |
| Share holding post issue | 119,565,000 |
Alkem Laboratories IPO offers 9,087,084 shares. 2,510,906 (27.63%) to QIB, 1,883,179 (20.72%) to NII, 4,394,086 (48.36%) to RII, 298,913 (3.29%) to employees. 313,863 RIIs will receive minimum 14 shares and (sNII) and (bNII) will receive minimum 196 shares. (in case of oversubscription)
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | - | NA |
| QIB Shares Offered | 2,510,906 (27.63%) | NA |
| NII (HNI) Shares Offered | 1,883,179 (20.72%) | |
| Retail Shares Offered | 4,394,086 (48.36%) | 313,863 |
| Employee Shares Offered | 298,913 (3.29%) | NA |
| Total Shares Offered | 9,087,084 (100%) |
Investors can bid for a minimum of 14 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,700 |
| Retail (Max) | 13 | 182 | ₹191,100 |
| Lot Size Calculator | |||
Alkem Labs has 23 Promoters who jointly hold 64,302,440 Equity Shares of the Company which, in aggregate, constitutes 53.8% of the issued and paid-up Equity Share capital of our Company.
| Share Holding Pre Issue | 70.87% |
| Share Holding Post Issue | 66.23% |
Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.
Alkem Labs produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 countries internationally, primarily the United States.
Company's pharmaceutical business is organized into domestic and international operations. Alkem Labs has a portfolio of over 736 brands in India. Company's most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients.
Alkem Labs have a total of 16 manufacturing facilities: 14 manufacturing facilities at five locations in India and two in the United States. Company have four research and development facilities, two in India and two in the United States. As of June 30, 2015, company employed 483 scientists in research and development functions.
Highlights:
1. Alkem Labs is 5th largest pharmaceutical company in India in terms of domestic sales.
2. Alkem Labs products are also sold in 56 countries. In the United States, company has filed 66 abbreviated new drug applications.
3. Company sells a range of high-quality, cost effective generic drugs to major drug chains, pharmaceutical retailers, wholesalers, food and grocery stores, distributors and managed care companies in the United States.
| Particulars | For the year/period ended (in Rs. Million) | |||
| 31 Mar 15 | 31 Mar 14 | 31 Mar 13 | 31 Mar 12 | |
| Total Income | 33,595.20 | 28,395.80 | 24,690.10 | 20,640.10 |
| Profit After Tax (PAT) | 4,370.90 | 4,402.00 | 4,667.80 | 4,318.10 |
| KPI | Values |
|---|---|
| RoNW | 15.4% |
The objects of the Offer are:
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and
2. For the sale of 12,853,442 Equity Shares by the Selling Shareholders.
[Dilip Davda]
Considering company's position, popular brands in the pharma sector and the given track records with over 22% CAGR in revenue growth for last five fiscals and over 36% growth in first half of current fiscal, reasonable pricing, it's a worthy bet for short to long term.
Read detail review...The Alkem Laboratories IPO is subscribed 44.29 times on December 10, 2015 11:15:00 PM. The public issue subscribed 3.17 times in the retail category, 57.19 times in the QIB category, and 129.96 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 57.19 |
| NII | 129.96 |
| Retail | 3.17 |
| Employee | 0.67 |
| Total | 44.29 |
| Listing Date | December 23, 2015 |
| BSE Script Code | 539523 |
| NSE Symbol | ALKEM |
| ISIN | INE540L01014 |
| Final Issue Price | ₹1050 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹1,050.00 |
| ₹1,380.00 |
| ₹1,355.40 |
| ₹1,410.00 |
| ₹1,381.45 |
| NSE |
|---|
| ₹1,050.00 |
| ₹1,380.00 |
| ₹1,356.20 |
| ₹1,413.70 |
| ₹1,381.70 |
Alkem Laboratories Limited
Alkem House,
Senapati Bapat Marg,
Lower Parel, Mumbai 400 013
Phone: +91 22 3982 9999
Email: investors@alkem.com
Website: http://www.alkemlabs.com/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: all.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Alkem Laboratories IPO is a main-board IPO of 12,853,442 equity shares of the face value of ₹2 aggregating up to ₹1,349.61 Crores. The issue is priced at ₹1020 to ₹1050 per share. The minimum order quantity is 14 Shares.
The IPO opens on December 8, 2015, and closes on December 10, 2015.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
The Alkem Laboratories IPO opens on December 8, 2015 and closes on December 10, 2015.
Alkem Laboratories IPO lot size is 14 Shares, and the minimum amount required is ₹14,700.
You can apply in Alkem Laboratories IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Alkem Laboratories IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Alkem Laboratories IPO allotment status.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
